R2R01 Plus Terlipressin Versus Terlipressin Alone in Hepatorenal Syndrome–Acute Kidney Injury

Phase 2, randomised, single-blind trial of R2R01 in hepatorenal syndrome (HRS), acute kidney failure (AKF), Cirrhosis and 1 more (2 arms), sponsored by River 2 Renal Corp. Primary endpoints: Safety and tolerability, Incidence of responders (Established HRS reversal) and 2 more. Started Oct 2023; status: completed.